Introduction {#S0001}
============

Acute coronary syndromes (ACS) remain one of the leading causes of premature demise in men and women despite unquestionable progress in the management and prevention of coronary artery disease (CAD) \[[@CIT0001]\]. Some classical cardiovascular risk factors, common in the young nowadays, such as smoking, obesity, impaired glucose tolerance, diabetes, dyslipidemia, hyperhomocysteinemia and emotional stress, lead to premature coronary atherosclerosis. Others, being revealed at a younger age and not very prevalent, such as congenital coronary abnormalities, connective tissue disorders, increased matrix metalloproteinase activity, coronary artery aneurysm, coronary artery dissection, myocardial bridging, irradiation, illicit drug usage and acquired or congenital hypercoagulability syndromes, may cause an abrupt blood flow cessation due to endothelial dysfunction and coronary artery spasm as well as rapid clot formation \[[@CIT0002], [@CIT0003]\]. As myocardial infarction is believed to affect mainly older people, preventive measures are not always a goal in the young. A lot of impressive papers referring to different gender-related issues of ACS have been published so far \[[@CIT0004]--[@CIT0007]\]. A female pattern of CAD is related to the high prevalence of non-obstructive eccentric lesions, excessive distal embolization and a tendency toward different structure of the eroded plaque with predominant smooth muscle cells and proteoglycans \[[@CIT0008]\]. Women with STEMI have an increased risk of in-hospital death and their long-term prognosis is worse than their male counterparts \[[@CIT0005], [@CIT0009], [@CIT0010]\]; however, there are not many reports on the long-term prognosis in patients with ST-segment elevation myocardial infarction (STEMI) younger than forty. Moreover, in the available literature some contradictory results may be found \[[@CIT0006], [@CIT0009], [@CIT0011]\]. Some studies were single-center and some mixed different types of acute coronary syndromes.

To further investigate this issue we analyzed a population of 527 consecutive patients aged 20-40 years and their one-year prognosis after STEMI.

Material and methods {#S0002}
====================

Patients and data collection {#S20003}
----------------------------

In-hospital data analysis was approved by administrators of the Polish National Acute Coronary Syndrome Registry (PL-ACS), which was carried out by the Silesian Centre for Heart Diseases in Zabrze in cooperation with the National Health Fund as part of the National Program for Prevention and Treatment of Cardiovascular Diseases launched by the Polish Ministry of Health. The principles of the PL-ACS registry have been reported elsewhere \[[@CIT0012]\] and are available on-line \[[@CIT0013]\]. Briefly, the registry includes data on patients with ACS from 456 sites in the country with mandatory data collection. We analyzed all 527 consecutive men and women (12.3% females) aged from 20 to 40 years (mean 35.7 ±4.5 years) presenting with STEMI, of all 26 035 STEMI patients enrolled in the PL-ACS between June 2005 and May 2006. The collected data included age, gender, concomitant diseases, coronary risk factors, previous myocardial infarction and revascularization, time from symptoms onset to admission and reperfusion, extent of the disease in angiography, TIMI flow before and after revascularization, adjunctive treatment, left ventricular ejection fraction (LVEF), complications and medication. Mortality data (in-hospital and 1-year follow-up) after hospital discharge were obtained from the National Health Fund and Civil Registry database and were collected for all included subjects.

Ethics {#S20004}
------

The study was approved by the Ethics Committee of the local division of the Polish Chamber of Physicians.

Statistical analysis {#S20005}
--------------------

Continuous variables are expressed as mean ± standard deviation or median and interquartile range as appropriate. The significance of differences between groups was determined using Student\'s *t* test or the Mann-Whitney *U* test for those variables which did not conform to a normal distribution. Homogeneity of variances was tested using the *F* test. Categorical variables were tested using the χ^2^ test. Mortality after 12 months was analyzed using Kaplan-Meier method with a log-rank test. Cox proportional hazards regression was used to adjust mortality for demographic and clinical variables and results are presented as relative risk (RR) and 95% confidence intervals (CI). A *p* value \< 0.05 was considered statistically significant. Calculations and statistical analyses were carried out with Statistica PL software, version 6.1 (StatSoft Inc.).

Results {#S0006}
=======

Clinical characteristics of the study group {#S20007}
-------------------------------------------

Of all 26 035 patients with STEMI, 2.02% of those were under forty. There were no significant differences between genders in the basic clinical characteristics (major cardiovascular risk factors, clinical presentation, extent of the disease and time to reperfusion) except for more frequent obesity in women and more frequent moderately decreased left ventricular ejection fraction in men. There was a slight tendency with borderline significance toward more risky cardiovascular profile in women, i.e. diabetes or Killip class on admission ([Table I](#T0001){ref-type="table"}).

###### 

Basic clinical characteristics

  Variable                             Females, *n* = 65 (%)   Males, *n* = 462 (%)   Value of *p*
  ------------------------------------ ----------------------- ---------------------- --------------
  Major risk factors                                                                  
   Age \[years\]                       36.1 ±4.0               35.6 ±4.6              0.44
   Hypertension                        24 (36.9)               153 (33.1)             0.54
   Diabetes                            7 (10.8)                21 (4.5)               0.072
   Hypercholesterolemia                23 (35.4)               166 (35.9)             0.93
   Smoking                             41 (63.1)               310 (67.1)             0.52
   Obesity (BMI \> 30 kg/m^2^)         15 (23.1)               60 (13)                0.029
   Prior MI                            3 (4.6)                 30 (6.5)               0.76
   Prior PCI                           0 (0)                   3 (0.6)                0.82
   Prior CABG                          2 (3.1)                 20 (4.3)               0.89
   Atrial fibrillation                 0 (0)                   6 (1.3)                0.76
   Heart rate \[bpm\]                  81 ±17                  78 ±17                 0.18
   Cardiac arrest                      4 (6.2)                 22 (4.8)               0.86
  Infarct location                                                                    
   Anterior                            29 (44.6)               182 (39.4)             0.42
   Inferior                            31 (47.7)               225 (48.7)             0.88
  Onset-to-door time \[h\]                                                            
   0-3                                 23 (37.1)               168 (38.9)             0.79
   3-12                                26 (41.9)               168 (38.9)             0.65
   \> 12                               13 (21)                 96 (22.2)              0.82
  Killip class                                                                        
   4                                   6 (9.2)                 17 (3.7)               0.084
   3                                   0 (0)                   1 (0.2)                0.25
   1 or 2                              59 (90.8)               444 (96.1)             0.11
  LVEF \[%\]                                                                          
   \> 50                               28 (75.7)               165 (60.2)             0.069
   30-50                               7 (18.9)                105 (38.3)             0.021
   \< 30                               2 (5.4)                 4 (1.5)                0.32
  Number of arteries diseased                                                         
   0                                   5 (10.4)                50 (16.4)              0.29
   1                                   32 (66.7)               187 (61.3)             0.48
   2                                   7 (14.6)                52 (17)                0.67
   ≥ 3                                 4 (8.3)                 16 (5.2)               0.60
  Onset-to-reperfusion times \[min\]                                                  
   Onset-to-lysis                      225 (162-382)           127 (60-360)           0.67
   Onset-to-balloon                    232 (180-358)           235 (179-370)          0.78

BMI -- body mass index, MI -- myocardial infarction, PCI -- percutaneous coronary intervention, CABG -- coronary artery bypass grafting, LVEF -- left ventricular ejection fraction

Therapeutic approach {#S20008}
--------------------

Fibrinolytic treatment was applied in 6.1% of patients whereas the majority (67%) underwent coronary angiography followed by primary percutaneous coronary intervention (PCI) in 79.9% of them ([Table II](#T0002){ref-type="table"}). A 92% reperfusion success rate measured by post-procedural TIMI 3 flow was achieved ([Table III](#T0003){ref-type="table"}). Women were more likely to receive diuretics (15.4% vs. 7.4%; *p* = 0.029), nitrates (25.4% vs. 14.1%; *p* = 0.02), insulin (10.8% vs. 3.5%; *p* = 0.018) and oral antihyperglycemic agents (3.1% vs. 0.2%; *p* = 0.047). There were no statistically significant differences between genders in the administration of acetylsalicylic acid, clopidogrel, heparin, β- and calcium channel blockers, statins and angiotensin-converting enzyme inhibitors both on admission and after discharge from hospital. The complication rate was very low and not significantly different between men and women ([Table IV](#T0004){ref-type="table"}).

###### 

Therapeutic approach

  Variable               Females *n* = 65 (%)   Males *n* = 462 (%)   Value of *p*
  ---------------------- ---------------------- --------------------- --------------
  Medical therapy        15 (23.1)              135 (29.2)            0.30
  Coronary angiography   48 (73.9)              305 (66.0)            0.21
  Anti-GP IIb/IIIa       15 (23.1)              94 (20.3)             0.81
  Thrombolysis           4 (6.2)                28 (6.1)              0.77
  PCI                    40 (61.5)              242 (52.4)            0.17

GP -- glycoprotein, PCI -- percutaneous coronary intervention

###### 

Pre- and postprocedural TIMI flow in patients who underwent PCI

  Variable                   Females *n* = 40 (%)   Males *n* = 242 (%)   Value of *p*
  -------------------------- ---------------------- --------------------- --------------
  Preprocedural TIMI flow                                                 
   0                         23 (57.5)              154 (63.6)            0.46
   1                         7 (17.5)               28 (11.6)             0.31
   2                         5 (12.5)               27 (11.2)             0.96
   3                         5 (12.5)               33 (13.6)             0.88
  Postprocedural TIMI flow                                                
   0                         2 (5)                  3 (1.2)               0.30
   1                         0 (0)                  3 (1.2)               0.89
   2                         1 (2.5)                14 (5.8)              0.65
   3                         37 (92.5)              222 (91.7)            0.85

TIMI -- Thrombolysis in Myocardial Infarction

###### 

In-hospital complications

  Variable       Females *n* = 65 (%)   Males *n* = 462 (%)   Value of *p*
  -------------- ---------------------- --------------------- --------------
  STEMI          2 (3.1)                15 (3.2)              0.76
  NSTEMI/UA      2 (3.1)                5 (1.1)               0.46
  Stroke         1 (1.5)                0 (0)                 0.25
  Bleeding       0 (0)                  0 (0)                 --
  Re-PCI (TLR)   1 (2.5)                0 (0)                 0.30

STEMI -- ST-segment elevation myocardial infarction, NSTEMI -- non-ST-segment elevation myocardial infarction, UA -- unstable angina, PCI -- percutaneous coronary intervention, TLR -- target lesion revascularization

Prognosis {#S20009}
---------

In-hospital and 30-day mortality were very low and therefore insignificant. However, the tendency of higher mortality in women started very early after discharge from hospital, became significant in the sixth month and continued to be significantly higher until the end of the observed period ([Table V](#T0005){ref-type="table"}, [Figure 1](#F0001){ref-type="fig"}). In the multivariate analysis three factors were found to influence mortality -- Killip class 3 or 4 on admission (RR 75.2, 95% CI 19.6-288.4), age per 5-year increase (RR 1.93, 95% CI 1.01-3.73), and primary PCI (RR 0.31, 95% CI 0.1-0.93) -- whereas all other factors included, as well as female sex, remained insignificant ([Figure 2](#F0002){ref-type="fig"}). When analyzing only patients who received reperfusion therapy (either PCI or fibrinolysis) there was a slight tendency towards higher mortality in women (7.1% vs. 1.9%; *p* = 0.046) ([Figure 3](#F0003){ref-type="fig"}).

![Kaplan-Meier 1-year mortality curves in men and women](AMS-9-20869-g001){#F0001}

![One-year mortality -- a multivariate analysis](AMS-9-20869-g002){#F0002}

![Kaplan-Meier 1-year mortality curves in patients who underwent reperfusion](AMS-9-20869-g003){#F0003}

###### 

Mortality in men and women

  Variable      Females *n* = 65 (%)   Males *n* = 462 (%)   Value of *p*
  ------------- ---------------------- --------------------- --------------
  In-hospital   2 (3.1)                7 (1.5)               0.69
  30-day        4 (6.2)                11 (2.4)              0.19
  6-month       7 (10.8)               13 (2.8)              0.0052
  12-month      7 (10.8)               14 (3.0)              0.003

Discussion {#S0010}
==========

At the beginning of the 20^th^ century in-hospital mortality in myocardial infarction reached 25-30%. Wide implementation of acute cardiac care units, fibrinolysis and primary PCI resulted in a 30-day mortality decrease to 8.4%. In large randomized controlled trials on fibrinolysis or primary PCI, 30-day mortality varies from 4% to 6% \[[@CIT0014]\]. Despite the progress, STEMI is one of the leading causes of mortality. In Poland, mortality after STEMI has decreased over the last decades, which is strongly associated with the progress in the management of patients with ACS, especially with a markedly developed network of primary PCI capable catheterization laboratories and modern pharmacotherapy (thienopyridines, glycoprotein IIb/IIIa inhibitors, renin-angiotensin-aldosterone system inhibitors, statins and β-blockers) \[[@CIT0015]\]. Young women are usually believed to have a lower cardiovascular risk as they are under the protective influence of estrogens. Gender-related differences in the management and prognosis have been widely documented in STEMI patients. In general, women with STEMI are older and have more cardiovascular risk factors and are also more prone to complications both of the disease and treatment \[[@CIT0009]\]. There are some conflicting reports of either no association of early mortality with sex and age \[[@CIT0016]\], a worse prognosis only for older women \[[@CIT0011]\] or only in younger women \[[@CIT0017]\] after myocardial infarction. Studies investigating long-term mortality after STEMI with reference to menopausal status are lacking.

Acute myocardial infarction in young persons represents from 2% to 10% of all ACS cases \[[@CIT0018]\] and usually affects males with a high disproportion to females, which is consistent with our findings. A disproportionate number of females may raise concern about data completeness or selection bias and therefore about the strength of the conclusions. In our observation the ratio of females to males is about 1: 7, which is consistent with findings presented by others or is even more in favor of the female subgroup. Despite the fact that STEMI should be considered as a secondary one to another underlying disease typical for this subset of patients, the cause may be coronary atherosclerosis \[[@CIT0002]\]. The most common risk factor in young patients is smoking, with much higher prevalence than in an older group \[[@CIT0019]\]. Poor basic clinical characteristics of women with STEMI (significantly more frequent hypertension, obesity, diabetes, anterior MI, atrial fibrillation, cardiogenic shock or pulmonary edema and longer onset-to-reperfusion time than in men) are reported in numerous papers as an explanation of the unfavorable prognosis in women. The above statements are true for any population with STEMI but without an age restriction. The question is whether these explanations fully satisfy the reader in the context of the present study results. In our group women had the classical coronary risk factor profile similar to their male counterparts, except for more frequent obesity. In a few reports there were some important findings that younger patients have more frequent history of parental coronary artery disease or a specific lipid phenotype \[[@CIT0020], [@CIT0021]\]. In the study group the incidence of some manifestations of CAD prior to the index ACS was very low. Unfortunately, data concerning parental history of CAD have not been collected. There was no difference in the prevalence of hypercholesterolemia. Another finding of ours, confirmed by others \[[@CIT0019]\], is that more than 60% of younger patients were current smokers. When compared to all patients included in the registry \[[@CIT0022]\], it is three times higher in women and almost twice as high in men, but still significant (*p* \< 0.001; data not presented here). In a multivariate analysis smoking did not influence long-term mortality, but two other factors (cardiogenic shock and age) were much more powerful. Although the beneficial effect of immediate blood flow restoration is certain, in many registries \[[@CIT0009]\] women are less likely to receive reperfusion therapy within a suggested timeframe, which results in a longer total ischemic time, larger extent of necrosis and heart failure, and therefore in a worse long-term prognosis. In our population there were no significant differences between men and women in time delays from symptoms onset to reperfusion. Moreover, the extent of the disease (single vs. multivessel disease) and a high post-procedural success rate (TIMI 3 flow) were similarly distributed within genders. What is most important, the majority of women (73.9%) had angiography and most of them PCI performed. Even the PCI to angiography ratio, usually greater in males due to lower PCI eligibility in women (smaller vessel size and greater tortuousness, pre-procedural TIMI 3 flow), in our study was greater in women, which excludes a referral bias. There were no significant differences in adjunctive and post-discharge pharmacotherapy as well as in in-hospital complication rates between genders. Some authors, although not supported by others' findings, ascribe the risk of higher in-hospital mortality in women to a greater incidence of pre-hospital cardiac deaths (therefore not included in registries) in men \[[@CIT0009]\]. Even if this is correct, it only explains early mortality. In our study the incidence of pre- and in-hospital cardiac arrest was insignificant and did not influence mortality in multivariate analysis.

To further explore reasons for higher mortality in women, it would be useful to investigate the correlation between some prognostic parameters (e.g. LVEF) and mortality, as it is commonly known that prognosis after STEMI is poor in individuals with significantly decreased LVEF \[[@CIT0014]\]. Surprisingly, males had a moderately decreased LVEF (30-50%) more frequently than females (38.3% vs. 18.9%; *p* = 0.021), whereas there were no differences in the frequency of normal (\> 50%) and significantly decreased (\< 30%) LVEF.

Doubtless a prompt restoration of the blood flow in an infarct-related artery preferably by primary PCI followed by appropriate pharmacotherapy is beneficial in all eligible patients. Even in the subgroup of patients who underwent acute reperfusion (either fibrinolysis or PCI) the mortality rate in women is higher. The most important finding of our analysis is that women under forty affected by STEMI have higher long-term mortality than their male counterparts regardless of the management strictly according to guidelines. In a study by Fournier *et al*. \[[@CIT0018]\] the overall mortality rate of 104 patients having STEMI under the age of 40 was 25.5% at 15 years, which confirms findings that individuals younger than forty who are STEMI survivors have a very poor long-term prognosis. In the study by Lawesson *et al*. \[[@CIT0023]\] in a large cohort of 2132 patients aged below 46 years, women had higher in-hospital but not long-term mortality when compared to men even though women had a worse clinical profile and their management was not strictly adherent to guidelines. This is completely opposite to our findings. However, there were some differences in post-discharge pharmacotherapy regarding β-blockers and statins as well as in the rate of post-discharge NYHA class IV in favor of men in Lawesson\'s study.

It is emphasized in many papers that crude gender-related differences in mortality depend on clinical presentation; however, these differences become less evident or even disappear after adjustment for clinical variables and angiographic findings \[[@CIT0024]\]. What is the most reliable explanation of the present study results that despite no difference in baseline characteristics and management according to guidelines mortality in women, even in those who underwent acute reperfusion, is still significantly higher? Twenty years after Healy\'s publication \[[@CIT0025]\] Dr C. Merz wrote in her editorial \[[@CIT0026]\] that "the Yentl syndrome is alive and well". So far, we have no proof to question this thesis.

Our registry, as all other registries, has some flaws. One of them is no registration of cause or type of STEMI (e.g. vulnerable plaque disruption vs. cocaine use etc.) and a lipid profile (except presence or absence of hypercholesterolemia), which would be of great importance in this subset of patients. Another problem is a disproportionate number of females as well as a low number of patients, especially the number of deaths during follow-up, which may bias the strength of statistical analyses and, therefore, the conclusions. Unfortunately, all authors reporting gender-related differences within the young with STEMI have the same difficulty. This is a result of the specific characteristics of this particular subset of patients. Therefore, the conclusions of our study should be adjusted to this limitation. To fully clarify the relationship of mortality to an index of myocardial infarction, it would be necessary to collect and analyze all causes of death. However, it was impossible to conduct such analyses. Finally, no data on parental history of premature MI or the extent of CAD have been collected.

In conclusion, in regard to the limitations considered above, borderline differences in some cardiovascular risk factors that could affect prognosis and low number of patients in the female group, it should be emphasized that any conclusions should be interpreted with caution and only in the context of the present study without extrapolation to the general population. Nonetheless, we conclude that despite almost similar baseline characteristics, no difference in time to reperfusion and even more guideline-compliant management in the population under forty, women with STEMI have higher long-term mortality than their male counterparts. This may question the myth that women are fully protected by estrogens and encourage further investigation of the problem of STEMI in very young people as well as intensification of primary prevention in this population.
